Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

被引:33
|
作者
Bolte, Laura A. [1 ,2 ,3 ]
Lee, Karla A. [4 ]
Bjork, Johannes R. [1 ,2 ,3 ]
Leeming, Emily R. [4 ]
Campmans-Kuijpers, Marjo J. E. [1 ,2 ]
de Haan, Jacco J. [1 ,2 ,5 ]
Vila, Arnau Vich [1 ,2 ,3 ]
Maltez-Thomas, Andrew [6 ]
Segata, Nicola [6 ,7 ]
Board, Ruth [8 ]
Harries, Mark [9 ]
Lorigan, Paul [10 ]
de Vries, Elisabeth G. E. [2 ,5 ]
Nathan, Paul [11 ]
Fehrmann, Rudolf [2 ,5 ]
Bataille, Veronique [4 ,12 ]
Spector, Tim D. [4 ]
Hospers, Geke A. P. [2 ,5 ]
Weersma, Rinse K. [1 ,2 ]
机构
[1] Univ Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[2] Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Groningen, Dept Genet, Groningen, Netherlands
[4] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England
[5] Univ Groningen, Dept Med Oncol, Groningen, Netherlands
[6] Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy
[7] European Inst Oncol, IRCSS, Milan, Italy
[8] Lancashire Natl Hlth Serv NHS Fdn Trust, Royal Preston Hosp, Dept Med Oncol, Fulwood, England
[9] Guys & St Thomass NHS Trust, Guys Canc Ctr, Dept Med Oncol, London, England
[10] Christie NHS Fdn Trust, Dept Dermatol, Manchester, England
[11] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, England
[12] West Hertfordshire NHS Trust, Dept Dermatol, Watford, England
关键词
IMMUNOTHERAPY; QUALITY; CANCER;
D O I
10.1001/jamaoncol.2022.7753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, isa poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB.OBJECTIVE To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021.EXPOSURES Patients were treated with anti-programmed cell death 1 and anti-cytotoxic T lymphocyte-associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment.MAIN OUTCOMES AND MEASURES Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher.RESULTS There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54).CONCLUSIONS AND RELEVANCE This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB.
引用
收藏
页码:705 / 709
页数:5
相关论文
共 50 条
  • [1] Long term outcomes of patients with advanced/unresectable melanoma treated with immune checkpoint inhibitors
    Sonke, Eric
    Angeles, Arkhjamil
    Nguyen, Thao Phuong
    Bahl, Gaurav
    Poon, Vincent Isaac
    Bernstein, Vanessa
    Weppler, Alison Margaret
    Savage, Kerry J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
    Buchbinder, Elizabeth I.
    Weirather, Jason L.
    Manos, Michael
    Quattrochi, Brian J.
    Sholl, Lynette M.
    Brennick, Ryan C.
    Bowling, Peter
    Bailey, Nancy
    Magarace, Lisa
    Ott, Patrick A.
    Haq, Rizwan
    Izar, Benjamin
    Giobbie-Hurder, Anita
    Hodi, F. Stephen
    CANCER MEDICINE, 2021, 10 (08): : 2627 - 2635
  • [3] Immune and Molecular Correlates in Melanoma Treated With Immune Checkpoint Blockade
    Byrne, Elizabeth H.
    Fisher, David E.
    CANCER, 2017, 123 : 2143 - 2153
  • [4] Predictors of responses to immune checkpoint blockade in advanced melanoma
    Jacquelot, N.
    Roberti, M. P.
    Enot, D. P.
    Rusakiewicz, S.
    Ternes, N.
    Jegou, S.
    Woods, D. M.
    Sodre, A. L.
    Hansen, M.
    Meirow, Y.
    Sade-Feldman, M.
    Burra, A.
    Kwek, S. S.
    Flament, C.
    Messaoudene, M.
    Duong, C. P. M.
    Chen, L.
    Kwon, B. S.
    Anderson, A. C.
    Kuchroo, V. K.
    Weide, B.
    Aubin, F.
    Borg, C.
    Dalle, S.
    Beatrix, O.
    Ayyoub, M.
    Balme, B.
    Tomasic, G.
    Di Giacomo, A. M.
    Maio, M.
    Schadendorf, D.
    Melero, I.
    Dreno, B.
    Khammari, A.
    Dummer, R.
    Levesque, M.
    Koguchi, Y.
    Fong, L.
    Lotem, M.
    Baniyash, M.
    Schmidt, H.
    Svane, I. M.
    Kroemer, G.
    Marabelle, A.
    Michiels, S.
    Cavalcanti, A.
    Smyth, M. J.
    Weber, S.
    Eggermont, A. M.
    Zitvogel, L.
    NATURE COMMUNICATIONS, 2017, 8
  • [5] Predictors of responses to immune checkpoint blockade in advanced melanoma
    N. Jacquelot
    M. P. Roberti
    D. P. Enot
    S. Rusakiewicz
    N. Ternès
    S. Jegou
    D. M. Woods
    A. L. Sodré
    M. Hansen
    Y. Meirow
    M. Sade-Feldman
    A. Burra
    S. S. Kwek
    C. Flament
    M. Messaoudene
    C. P. M. Duong
    L. Chen
    B. S. Kwon
    A. C. Anderson
    V. K. Kuchroo
    B. Weide
    F. Aubin
    C. Borg
    S. Dalle
    O. Beatrix
    M. Ayyoub
    B. Balme
    G. Tomasic
    A. M. Di Giacomo
    M. Maio
    D. Schadendorf
    I. Melero
    B. Dréno
    A. Khammari
    R. Dummer
    M. Levesque
    Y. Koguchi
    L. Fong
    M. Lotem
    M. Baniyash
    H. Schmidt
    I. M. Svane
    G. Kroemer
    A. Marabelle
    S. Michiels
    A. Cavalcanti
    M. J. Smyth
    J. S. Weber
    A. M. Eggermont
    L. Zitvogel
    Nature Communications, 8
  • [6] Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
    Johannes R. Björk
    Laura A. Bolte
    Andrew Maltez Thomas
    Karla A. Lee
    Niccolo Rossi
    Thijs T. Wind
    Lotte M. Smit
    Federica Armanini
    Francesco Asnicar
    Aitor Blanco-Miguez
    Ruth Board
    Neus Calbet-Llopart
    Lisa Derosa
    Nathalie Dhomen
    Kelly Brooks
    Mark Harland
    Mark Harries
    Paul Lorigan
    Paolo Manghi
    Richard Marais
    Julia Newton-Bishop
    Luigi Nezi
    Federica Pinto
    Miriam Potrony
    Susana Puig
    Patricio Serra-Bellver
    Heather M. Shaw
    Sabrina Tamburini
    Sara Valpione
    Levi Waldron
    Laurence Zitvogel
    Moreno Zolfo
    Elisabeth G. E. de Vries
    Paul Nathan
    Rudolf S. N. Fehrmann
    Tim D. Spector
    Véronique Bataille
    Nicola Segata
    Geke A. P. Hospers
    Rinse K. Weersma
    Nature Medicine, 2024, 30 : 785 - 796
  • [7] Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
    Bjork, Johannes R.
    Bolte, Laura A.
    Thomas, Andrew Maltez
    Lee, Karla A.
    Rossi, Niccolo
    Wind, Thijs T.
    Smit, Lotte M.
    Armanini, Federica
    Asnicar, Francesco
    Blanco-Miguez, Aitor
    Board, Ruth
    Calbet-Llopart, Neus
    Derosa, Lisa
    Dhomen, Nathalie
    Brooks, Kelly
    Harland, Mark
    Harries, Mark
    Lorigan, Paul
    Manghi, Paolo
    Marais, Richard
    Newton-Bishop, Julia
    Nezi, Luigi
    Pinto, Federica
    Potrony, Miriam
    Puig, Susana
    Serra-Bellver, Patricio
    Shaw, Heather M.
    Tamburini, Sabrina
    Valpione, Sara
    Waldron, Levi
    Zitvogel, Laurence
    Zolfo, Moreno
    de Vries, Elisabeth G. E.
    Nathan, Paul
    Fehrmann, Rudolf S. N.
    Spector, Tim D.
    Bataille, Veronique
    Segata, Nicola
    Hospers, Geke A. P.
    Weersma, Rinse K.
    NATURE MEDICINE, 2024, 30 (03) : 785 - 796
  • [8] Characterising the cfDNA Methylome in Patients with Metastatic Melanoma Treated with Immune Checkpoint Blockade
    Cooper, R.
    de los Aires, A. V.
    Nassiri, I.
    Taylor, C.
    Watson, R.
    Sharma, P. Kumar
    Tong, O.
    Mahe, E.
    Danielli, S.
    Fairfax, B.
    JOURNAL OF PATHOLOGY, 2021, 255 : S40 - S40
  • [9] Bone metastasis as an independent prognostic factor for survival in patients with advanced melanoma treated with immune checkpoint blockade.
    Teixeira, Marcos Rezende
    De Barros E Silva, Milton Jos
    Pandolfi, Natasha Carvalho
    Calsavara, Vinicius Fernando
    Oliveira, Thiago Bueno
    Tavares, Monique Celeste
    Rinck, Jose Augusto
    Garcia, Daniel
    Lima, Joao Paulo S. N.
    Duprat, Joao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
    Spillane, Susan
    Baxi, Shrujal
    Torres, Aracelis Z.
    Lenis, David
    Freedman, Andrew N.
    Mariotto, Angela B.
    Sharon, Elad
    ONCOLOGIST, 2020, 25 (11): : E1753 - E1762